Skip to main content

Table 1 Clinical trials of gp96 tumor vaccine in glioma

From: Immunotherapy with heat shock protein 96 to treat gliomas

NCT Number Start Date Location Sponsor/Collaborators Enrollment Disease Interventions Status
NCT00293423 2005/10/1 US UCSF Department of Neurosurgery San Francisco, California, United States, 41 Adult glioblastoma;Recurrent adult brain tumor HSPPC-96a with Temozolomide and radiotherapy Completed
NCT00905060 2009/6/1 US University of California, San Francisco 70 Newly diagnosed GBM HSPPC-96 with Temozolomide and radiotherapy Completed
NCT01814813 2013/5/1 US Alliance for Clinical Trials in Oncology 90 Recurrent Glioblastoma; HSPPC-96 with bevacizumab Active, not recruiting
T02122822 2013/7/1 China Beijing Tiantan Hospital Affiliated to Capital Medical University, Beijing, China 20 Supratentoria Glioma HSPPC-96 with Temozolomide and radiotherapy Completed
NCT02722512 2016/7/1 US Ann & Robert H Lurie Children's Hospital of Chicago | Northwestern University 20 GBM; Astrocytoma;Anaplastic Ependymoma HSPPC-96 with Radiation Recruiting
NCT03018288 2017/9/21 US National Cancer Institute (NCI) | National Institutes of Health Clinical Center (CC) 108 Glioblastoma HSPPC-96 with radiation, temozolomide and Pembrolizumab-96 Recruiting
NCT03650257 2018/8/20 China Beijing Tiantan Hospital Affiliated to Capital Medical University, Beijing, China 150 Glioma of Brain HSPPC-96 with Temozolomide and radiotherapy Recruiting
  1. aHSPPC-96 Heat shock protein peptide complex-96